BLUA vs. ANIK, OSUR, NVRO, GUTS, CERS, TMCI, SKIN, TCMD, LUNG, and SGHT
Should you be buying BlueRiver Acquisition stock or one of its competitors? The main competitors of BlueRiver Acquisition include Anika Therapeutics (ANIK), OraSure Technologies (OSUR), Nevro (NVRO), Fractyl Health (GUTS), Cerus (CERS), Treace Medical Concepts (TMCI), Beauty Health (SKIN), Tactile Systems Technology (TCMD), Pulmonx (LUNG), and Sight Sciences (SGHT). These companies are all part of the "surgical & medical instruments" industry.
Anika Therapeutics (NASDAQ:ANIK) and BlueRiver Acquisition (NYSE:BLUA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, community ranking, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.
BlueRiver Acquisition has lower revenue, but higher earnings than Anika Therapeutics.
BlueRiver Acquisition has a net margin of 0.00% compared to BlueRiver Acquisition's net margin of -45.39%. BlueRiver Acquisition's return on equity of 0.48% beat Anika Therapeutics' return on equity.
91.5% of Anika Therapeutics shares are owned by institutional investors. Comparatively, 22.3% of BlueRiver Acquisition shares are owned by institutional investors. 5.9% of Anika Therapeutics shares are owned by insiders. Comparatively, 79.0% of BlueRiver Acquisition shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Anika Therapeutics received 300 more outperform votes than BlueRiver Acquisition when rated by MarketBeat users.
In the previous week, Anika Therapeutics had 7 more articles in the media than BlueRiver Acquisition. MarketBeat recorded 7 mentions for Anika Therapeutics and 0 mentions for BlueRiver Acquisition. BlueRiver Acquisition's average media sentiment score of 0.40 beat Anika Therapeutics' score of 0.00 indicating that Anika Therapeutics is being referred to more favorably in the media.
Anika Therapeutics presently has a consensus price target of $30.50, suggesting a potential upside of 18.91%. Given BlueRiver Acquisition's higher possible upside, equities analysts clearly believe Anika Therapeutics is more favorable than BlueRiver Acquisition.
Summary
Anika Therapeutics beats BlueRiver Acquisition on 9 of the 12 factors compared between the two stocks.
Get BlueRiver Acquisition News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLUA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BLUA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BlueRiver Acquisition Competitors List
Related Companies and Tools
